BiotechTube

Quetiapine fumarate + Paroxetine

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Generalized Anxiety Disorder

Conditions

Generalized Anxiety Disorder

Trial Timeline

May 1, 2006 → May 1, 2007

NCT ID
NCT00322595

About Quetiapine fumarate + Paroxetine

Quetiapine fumarate + Paroxetine is a phase 3 stage product being developed by AstraZeneca for Generalized Anxiety Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00322595. Target conditions include Generalized Anxiety Disorder.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00322595Phase 3Completed

Competing Products

20 competing products in Generalized Anxiety Disorder

See all competitors
ProductCompanyStageHype Score
atomoxetine + placeboEli LillyPhase 2/3
65
SatralizumabChugai PharmaceuticalPhase 3
77
PerampanelEisaiPre-clinical
23
Perampanel + Placebo comparatorEisaiPhase 3
77
zonisamideEisaiPre-clinical
23
FycompaEisaiPre-clinical
23
FycompaEisaiPre-clinical
23
PerampanelEisaiPhase 3
77
PerampanelEisaiPre-clinical
23
CenobamateOno PharmaceuticalPhase 3
77
Duloxetine + PlaceboEli LillyPhase 3
77
Duloxetine + PlaceboEli LillyApproved
85
IxekizumabEli LillyApproved
85
eszopiclone + eszopiclone + PlaceboSumitomo PharmaPhase 2
52
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved
85
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)AbbViePhase 2
52
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/dayAbbViePhase 2
52
ABBV-932 + PlaceboAbbViePhase 1
33
EscitalopramAbbVieApproved
85
AdalimumabAbbViePhase 3
77

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85